Munich Hall Industry Satellite Symposium

Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer (ID 36)

Date
Fri, 12.05.2023
Time
12:30 - 13:30
Room
Munich Hall
Chairs
  • Wolfgang Janni (Ulm, Germany)
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Welcome and introduction - Treatment landscape and emerging needs in metastatic breast cancer: Where are we today? (ID 95)

Lecture Time
12:30 - 12:40
Session Name
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer
Room
Munich Hall
Date
Fri, 12.05.2023
Time
12:30 - 13:30
Speakers
  • Wolfgang Janni (Ulm, Germany)
Authors
  • Wolfgang Janni (Ulm, Germany)
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Optimal management in mTNBC: What have we learned from clinical practice? (ID 96)

Lecture Time
12:40 - 13:10
Session Name
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer
Room
Munich Hall
Date
Fri, 12.05.2023
Time
12:30 - 13:30
Speakers
  • Ana Mafalda Antunes De Melo e Oliveira (Barcelona, Spain)
Authors
  • Ana Mafalda Antunes De Melo e Oliveira (Barcelona, Spain)
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

A new era of treatment for HR+/HER2- mBC: What do the clinical data tell us? (ID 97)

Lecture Time
13:10 - 13:30
Session Name
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer
Room
Munich Hall
Date
Fri, 12.05.2023
Time
12:30 - 13:30
Speakers
  • Komal Jhaveri (New York, NY, United States of America)
Authors
  • Komal Jhaveri (New York, NY, United States of America)
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer

Closing remarks (ID 98)

Lecture Time
13:30 - 13:30
Session Name
Gilead Sciences - BREAKING THROUGH: Overcoming challenges in the treatment of patients with triple-negative and HR+/HER2-metastatic breast cancer
Room
Munich Hall
Date
Fri, 12.05.2023
Time
12:30 - 13:30
Speakers
  • Wolfgang Janni (Ulm, Germany)
Authors
  • Wolfgang Janni (Ulm, Germany)